Trial Profile
A Phase 2 Study of Pembrolizumab in Patients With Histiocyte/Dendritic Cell Neoplasms and Biologically Selected Subtypes of Relapsed/Refractory Aggressive Lymphomas
Status:
Suspended
Phase of Trial:
Phase II
Latest Information Update: 24 Nov 2023
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Diffuse large B cell lymphoma; Plasmablastic lymphoma; Sarcoma; T-cell lymphoma
- Focus Therapeutic Use
- 26 Aug 2022 Planned End Date changed from 31 May 2025 to 18 Aug 2024.
- 26 Aug 2022 Status changed from recruiting to suspended.
- 19 Jul 2021 Planned primary completion date changed from 31 May 2021 to 31 May 2022.